Microcytic Anaemia (Iron Deficiency vs Thalassaemia Trait/Mentzer Index), Haemolytic Anaemias (Spherocytosis, G6PD)

Pediatric Anemias: Age-Adjusted Norms, Microcytic Differentials, and Congenital Hemolytic Disorders

Anemia is one of the most frequent clinical presentations encountered in general and hospital pediatrics. Because childhood hematology is defined by dynamic developmental changes from the neonatal period through adolescence, the clinical approach to pediatric anemia requires anchoring laboratory values to age-specific reference intervals. Understanding the pathophysiological mechanisms governing red cell production, membrane integrity, and hemoglobin synthesis is essential for solving clinical vignettes on the European Board of Paediatrics (EBP-EAP) examination.

---

Age-Dependent Hemoglobin Norms and the Physiological Nadir

At birth, full-term infants possess elevated hemoglobin concentrations (140 to 200 g/L) with macrocytic indices (mean corpuscular volume [MCV] 100 to 120 fL). Fetal hemoglobin (HbF, α₂γ₂) comprises 60% to 80% of circulating hemoglobin, facilitating transplacental oxygen uptake due to its high oxygen affinity (shifted left on the oxygen-hemoglobin dissociation curve).

The Postnatal Transition and Physiological Nadir

Delivery and the initiation of spontaneous ventilation trigger profound changes in oxygen kinetics:

1. Downregulation of Erythropoietin (EPO): After birth, lung aeration and increased arterial oxygenation improve tissue oxygen delivery. This reduces the stimulus for erythropoietin production, so circulating EPO concentrations fall and erythropoiesis is temporarily suppressed. Combined with shorter neonatal red-cell survival, this produces the physiological fall in hemoglobin.
2. The Physiological Nadir of Infancy: With erythropoiesis temporarily suppressed and red blood cell lifespan shortened in neonates (60–90 days versus 120 days in adults), hemoglobin progressively declines, reaching a physiological nadir between 8 and 12 weeks of age in healthy term infants, with hemoglobin dipping to 90 to 110 g/L (9.0–11.0 g/dL). Erythrocytes remain normocytic and normochromic, and reticulocyte counts drop transiently.
3. Rebound Erythropoiesis: As somatic growth continues and tissue metabolic demand rises, tissue hypoxia stimulates renewed renal EPO secretion around 3 to 4 months of age, driving reticulocytosis and normalizing hemoglobin levels.
4. Anemia of Prematurity: In preterm infants (<37 weeks gestation, particularly very low birth weight [<1500 g] neonates), the physiological nadir occurs earlier (at 4 to 8 weeks), reaches a significantly deeper nadir (hemoglobin frequently falling below 70 to 80 g/L), and is exacerbated by diminished initial red cell mass, truncated placental iron transfer, shorter red cell survival (40–60 days), and frequent iatrogenic phlebotomy losses.

---

Algorithmic Approach to Childhood Anemias by Mean Corpuscular Volume (MCV)

Pediatric anemias are systematically categorized by mean corpuscular volume (MCV) into microcytic, normocytic, and macrocytic categories. Because adult MCV thresholds cannot be applied to children, pediatric clinicians evaluate MCV against age-adjusted reference ranges, using the approximation Lower Limit of Normal MCV (fL) = 70 + age in years for ages 1–10 years; use laboratory age-specific ranges outside this interval.

                              [Pediatric Anemia Workup]
                                          |
                  +-----------------------+-----------------------+
                  |                       |                       |
        [Microcytic (Low MCV)]   [Normocytic (Normal MCV)]   [Macrocytic (High MCV)]
        - Iron Deficiency        - Acute Blood Loss          - B12 / Folate Deficiency
        - Beta-Thalassemia Trait - Hemolysis (immune/membr.) - Hypothyroidism
        - Alpha-Thalassemia Trait- Anemia of Chronic Dis.    - Fanconi Anemia
        - Lead Poisoning         - Transient Erythroblast.   - Diamond-Blackfan Anemia
        - Sideroblastic Anemia     of Childhood (TEC)        - Bone Marrow Failure

Normocytic and Macrocytic Differentials of High Clinical Yield

• Transient Erythroblastopenia of Childhood (TEC): A self-limiting, acquired pure red cell aplasia occurring between 1 and 4 years of age, often following an uncharacterized viral infection. Patients present with severe, insidious normocytic anemia (Hb 40–80 g/L) with profound reticulocytopenia (<0.1%), normal white blood cells and platelets, and absent physical anomalies. Bone marrow recovers spontaneously within 4 to 8 weeks; red cell adenosine deaminase (eADA) is characteristically normal (differentiating TEC from congenital red cell aplasias).
• Diamond-Blackfan Anemia (DBA): A rare congenital pure red cell aplasia manifesting within the first year of life (usually by 2–3 months). Features include macrocytic anemia, reticulocytopenia, elevated erythrocyte adenosine deaminase (eADA), and characteristic physical anomalies in 50% of patients: triphalangeal or hypoplastic thumbs, craniofacial dysmorphism (hypertelorism, micrognathia), short stature, and webbed neck. Managed with corticosteroids and chronic transfusions.
• Fanconi Anemia (FA): The most common inherited bone marrow failure syndrome, inherited primarily in an autosomal recessive pattern involving defective DNA repair complexes. It typically presents between 5 and 10 years of age with progressive macrocytic anemia that evolves into fatal aplastic pancytopenia. Hallmark physical signs include café-au-lait macules, hypopigmented patches, absent or hypoplastic thumbs and radius, short stature, microcephaly, and renal or structural urinary tract anomalies. Diagnosis is confirmed by demonstrating chromosomal breakage following exposure of peripheral blood lymphocytes to DNA cross-linking agents (diepoxybutane [DEB] or mitomycin C [MMC]).

---

Microcytic Hypochromic Anemias: Iron Deficiency vs Beta-Thalassaemia Trait

The vast majority of pediatric microcytic anemias represent either Iron Deficiency Anemia (IDA) or Beta-Thalassaemia Trait (Minor). Rapidly differentiating these conditions avoids unnecessary invasive testing or inappropriate, potentially toxic iron administration.

Iron Deficiency Anemia (IDA)

• Epidemiology and Dietary Triggers: Iron deficiency represents the single most common nutritional disorder worldwide. In toddlers aged 12 to 36 months, excessive consumption of unmodified cow's milk (>500 mL/day, or >16–20 oz/day) is the predominant cause. Cow's milk features low elemental iron content with poor bioavailability, induces early satiety displacing iron-dense complementary solid foods, and contains bovine calcium and casein that inhibit intestinal non-heme iron absorption. Furthermore, heat-labile bovine proteins cause subclinical intestinal mucosal inflammation resulting in occult microscopic enteric blood loss.
• Laboratory Profile:
  • Serum Ferritin: Reflects total body reticuloendothelial iron stores. A serum ferritin <12–15 mcg/L is the most specific biochemical marker for depleted iron reserves. However, ferritin is an acute-phase reactant and can be falsely normal or elevated in concurrent systemic inflammation or infection.
  • Soluble Transferrin Receptor (sTfR): Elevated in iron deficiency; critically, sTfR remains elevated even in the presence of systemic inflammation, serving as an outstanding discriminating tool when ferritin is equivocal.
  • Red Cell Distribution Width (RDW): Markedly elevated (RDW >15%), reflecting prominent anisocytosis (variation in erythrocyte size) as newly produced microcytes mix with older normocytic erythrocytes.
  • Total Iron-Binding Capacity (TIBC): Elevated, with a low transferrin saturation (<15%).
• Pharmacological Treatment of IDA:
  • Dosing: Oral elemental iron at 3 to 6 mg/kg/day (administered as ferrous sulfate, ferrous fumarate, or ferrous gluconate) divided once or twice daily.
  • Optimization: Administered between meals or with ascorbic acid (Vitamin C, e.g., fresh orange juice) to promote reduction of ferric (Fe³⁺) to absorbable ferrous (Fe²⁺) iron. Co-ingestion with dairy milk, tea, or antacids must be strictly avoided.
  • Duration of Therapy: Iron therapy must be continued for at least 3 months after normalization of hemoglobin to completely replenish exhausted reticuloendothelial bone marrow ferritin stores.
  • Expected Response: Reticulocytosis peaks at 5 to 7 days, followed by an increase in hemoglobin of at least 10 g/L within 3 to 4 weeks.
  • Dietary Modification: Limit whole cow's milk to less than 500 mL/day and introduce iron-fortified cereals, pulses, and heme-rich meats.

Beta-Thalassaemia Trait (Minor)

• Pathophysiology: Caused by heterozygous point mutations or deletions in the beta-globin gene (HBB on chromosome 11), leading to reduced (β⁺) or absent (β⁰) synthesis of beta-globin chains. Because alpha-globin chains are produced in normal quantities, relative alpha-chain excess causes mild, ineffective erythropoiesis, but the marrow compensates with robust erythroid hyperplasia.
• Laboratory Profile: Characterized by a mild microcytic hypochromic anemia (hemoglobin typically 95–115 g/L) with disproportionately profound microcytosis (MCV typically 55 to 70 fL, often far lower than seen in an equivalent degree of iron deficiency). Total red blood cell count is physiologically elevated (RBC count >5.0 to 5.5 × 10¹²/L). RDW remains uniform and normal (RDW <14%). Serum ferritin and iron studies are normal in isolated trait; coexisting iron deficiency must be assessed separately.
• Diagnostic Confirmation: Hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) reveals elevated Hemoglobin A2 (HbA2 >3.5%) and occasionally slightly elevated HbF (1–3%).

The Mentzer Index

The Mentzer Index is a validated, rapid screening calculation utilizing routine complete blood count parameters to differentiate iron deficiency from beta-thalassemia trait:

$$\text{Mentzer Index} = \frac{\text{MCV (fL)}}{\text{RBC Count } (10^{12}\text{/L})}$$

• Mentzer Index > 13: Strongly indicates Iron Deficiency Anemia. In IDA, both iron deficiency and diminished red cell production drive MCV down, but the red blood cell count drops substantially, yielding a higher ratio.
• Mentzer Index < 13: Strongly indicates Beta-Thalassaemia Trait. In thalassaemia trait, red cell production remains intense (producing a high RBC count) while individual cells are extremely microcytic, generating a low ratio.

---

Congenital Hemolytic Anemias

Hemolytic anemias are characterized by premature red blood cell destruction (lifespan <120 days). The classic clinical triad comprises pallor, unconjugated hyperbilirubinemic jaundice, and splenomegaly. Laboratory hallmarks of active hemolysis include elevated reticulocytes (>2–3%), elevated serum lactate dehydrogenase (LDH), reduced or undetectable haptoglobin, and hemoglobinuria/hemosiderinuria in intravascular hemolysis.

Hereditary Spherocytosis (HS)

• Genetics and Cytoskeleton Pathology: Hereditary spherocytosis is the most common inherited hemolytic anemia in Northern European populations (prevalence ~1 in 2,000). It is inherited in an autosomal dominant pattern in 75% of cases (with 25% representing de novo mutations or recessive inheritance). The underlying molecular defect involves abnormalities in red cell membrane cytoskeletal proteins:
  • Ankyrin (ANK1): Most frequent defect (50%)
  • Band 3 (SLC4A1): ~20%
  • Beta-Spectrin (SPTB) and Protein 4.2 (EPB42)
• Pathogenesis: Disruption of vertical linkages between the lipid bilayer and the spectrin cytoskeleton causes progressive loss of membrane surface area via microvesiculation without proportional loss of intracellular volume. Erythrocytes lose their flexible biconcave disk architecture and transform into rigid, spherical cells (spherocytes) with diminished deformability. As spherocytes pass through the tortuous, acidic, and hypoxic cords of Billroth in the spleen, they cannot traverse the narrow endothelial slits into the sinusoids. Splenic macrophages phagocytose the entrapped spherocytes, resulting in chronic extravascular hemolysis.
• Clinical Presentation:
  • Neonatal period: Pathological unconjugated hyperbilirubinemia often requiring intensive phototherapy or exchange transfusion.
  • Childhood: Chronic compensated or uncompensated hemolytic anemia, fluctuating mild scleral icterus, and progressive splenomegaly.
  • Pigment Gallstones (Cholelithiasis): Chronic bilirubin hypersecretion leads to calcium bilirubinate gallstones in up to 50% of untreated adolescents.
  • Aplastic Crisis: Triggered by Parvovirus B19 infection. Parvovirus B19 selectively infects and arrests erythroblast progenitors in the bone marrow. In a child with baseline red cell survival of only 15 to 20 days, temporary cessation of erythropoiesis causes an abrupt, life-threatening drop in hemoglobin accompanied by reticulocytopenia (<0.1%).
• Diagnostic Evaluation:
  • Peripheral blood film: Abundant small, round, hyperchromic microspherocytes lacking central pallor, accompanied by polychromasia.
  • Indices: Mean Corpuscular Hemoglobin Concentration is characteristically elevated (MCHC >350 to 360 g/L) due to cellular dehydration.
  • Direct Antiglobulin Test (DAT / Direct Coombs): Characteristically negative, distinguishing HS from autoimmune hemolytic anemia (AIHA).
  • Flow Cytometry (EMA Binding Test): The Eosin-5-maleimide (EMA) binding test is a recommended first-line screening test when the diagnosis is uncertain. EMA binds to Band 3 and associated membrane complexes; HS red cells show reduced mean fluorescence intensity. Interpret the result with the family history, blood film and indices. Cryohaemolysis is another recommended screen; osmotic fragility is not recommended for routine screening.
• Management:
  • Folic Acid Supplementation: Daily oral folic acid (e.g., 1 mg/day) is recommended in moderate or severe HS; routine supplementation is unnecessary in mild disease.
  • Splenectomy Indications and Rules: Splenectomy is recommended for severe HS, considered for symptomatic moderate disease, and usually unnecessary for mild disease. It reduces hemolysis and anemia but leaves the membrane defect and spherocytes. Because Overwhelming Post-Splenectomy Infection (OPSI), particularly pneumococcal infection, remains a lifelong risk, elective surgery is preferably deferred until at least 6 years of age.
  • Pre- and Post-Splenectomy Prophylaxis: Complete pneumococcal, meningococcal and indicated Hib vaccination according to age, previous doses and current national asplenia schedules, ideally at least 2 weeks before elective surgery. Give daily Penicillin V prophylaxis after splenectomy; duration depends on age, time since surgery and continuing risk, with lifelong treatment for high-risk patients. Fever requires urgent assessment and parenteral antibiotics.

Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency

• Genetics and Enzymology: G6PD deficiency is the most common enzymatic red cell disorder, affecting over 400 million individuals globally. It is an X-linked recessive condition (G6PD gene on chromosome Xq28), predominantly affecting hemizygous males (though homozygous or Lyonized heterozygous females can manifest symptoms). Important variants include G6PD Mediterranean and G6PD A- (common in African populations), historically called Classes II and III. Both fall within current WHO Class B, associated with triggered acute haemolysis and median activity <45%. This classification describes genetic variants, not individual patients.
• Pathophysiology: G6PD catalyzes the conversion of glucose-6-phosphate to 6-phosphogluconolactone in the hexose monophosphate (pentose phosphate) shunt, generating NADPH. In erythrocytes—which lack mitochondria—the pentose phosphate shunt is the sole source of NADPH. NADPH is the obligate cofactor required by glutathione reductase to regenerate reduced glutathione (GSH). GSH acts as the primary intracellular antioxidant, neutralizing hydrogen peroxide and toxic reactive oxygen species (ROS). In G6PD deficiency, oxidative stress causes uncontrolled oxidation of sulfhydryl groups on hemoglobin, causing hemoglobin denaturation and precipitation into insoluble intracellular aggregates called Heinz bodies.

   [Glucose-6-Phosphate] + [NADP+] 
             | (G6PD enzyme)
             v
   [6-Phosphogluconolactone] + [NADPH] 
                                  |
                                  v
   [Oxidized Glutathione (GSSG)] ---> [Reduced Glutathione (GSH)]
                                            |
                                            v Neutralizes H2O2 & Free Radicals
                                    [Protects RBC Membrane & Hb]

• Oxidative Triggers:
  • Infections: The most common clinical trigger (viral upper respiratory infections, bacterial sepsis, hepatitis).
  • Dietary: Ingestion of fava beans (broad beans, Vicia faba), containing vicine and convicine which generate toxic divicine and isouramil (favism).
  • Medications: High-risk drugs include standard daily primaquine, tafenoquine, dapsone and rasburicase. Nitrofurantoin requires caution and monitoring; sulfamethoxazole has low-to-no haemolytic risk at standard doses under CPIC guidance.
  • Chemicals: Ingestion or inhalation of naphthalene (mothballs).
• Clinical Presentation: Typically asymptomatic between episodes. Following oxidative exposure (usually 24 to 72 hours later), patients develop acute, explosive hemolysis featuring both intravascular and extravascular red cell destruction. Symptoms include sudden pallor, jaundice, abdominal or lumbar back pain, and passing dark, reddish-brown "Coca-Cola" or port-wine colored urine (hemoglobinuria).
• Diagnostic Workup:
  • Peripheral Blood Film: Supravital staining (new methylene blue or crystal violet) reveals Heinz bodies. Standard Wright-Giemsa staining demonstrates "bite cells" (degmacytes: red cells where splenic macrophages have pitted out rigid Heinz body precipitates) and "blister cells" (eccentrocytes: red cells where oxidized hemoglobin has contracted away from the cell membrane).
  • Urinalysis: Positive for blood on dipstick (due to free hemoglobin) with an absence of intact red blood cells on microscopic sediment examination.
  • Diagnostic Caveat (The Reticulocyte Trap): During an acute hemolytic crisis, the oldest erythrocytes—possessing the lowest residual G6PD enzyme levels—are selectively hemolyzed first. The bone marrow responds with robust reticulocytosis. Because young reticulocytes and newly minted red cells have normal or elevated G6PD enzyme activity, a quantitative spectrophotometric G6PD enzyme assay performed during or immediately following an acute hemolytic episode can be falsely normal. Definitive enzymatic assay must be scheduled 2 to 3 months after the acute episode has completely resolved and reticulocytosis has subsided.
• Management: Primary therapy is prevention: provide families with advice on avoiding fava beans and high-risk oxidant drugs, and checking new medicines. During an acute hemolytic crisis, immediately discontinue any inciting pharmaceutical agent, maintain adequate hydration, using IV fluids when needed and monitoring urine output, renal function and fluid balance, and administer packed red blood cell transfusions for severe, symptomatic anemia.